伴有静脉瘤栓的睾丸生殖细胞瘤:发病率、表现和处理。

IF 5.4 3区 材料科学 Q2 CHEMISTRY, PHYSICAL ACS Applied Energy Materials Pub Date : 2024-08-14 DOI:10.1016/j.euf.2024.07.017
Sophia Y Chahine, Khalid Y Alkhatib, Gevorg Arakelyan, Claire Buxton, Gianluca Giannarini, Robert J Hamilton, Sarah K Holt, Jean-Christophe Bernhard, Di Maria Jiang, Daniel Lin, Jen-Jane Liu, Brandon Manley, Viraj A Master, Vsevolod Matveev, Andrea Necchi, Vignesh T Packiam, Sunil H Patel, Taylor Peak, Charles C Peyton, Phillip M Pierorazio, Gagan Prakash, Keyan Salari, Wade J Sexton, Nirmish Singla, Philippe E Spiess, Sarah P Psutka
{"title":"伴有静脉瘤栓的睾丸生殖细胞瘤:发病率、表现和处理。","authors":"Sophia Y Chahine, Khalid Y Alkhatib, Gevorg Arakelyan, Claire Buxton, Gianluca Giannarini, Robert J Hamilton, Sarah K Holt, Jean-Christophe Bernhard, Di Maria Jiang, Daniel Lin, Jen-Jane Liu, Brandon Manley, Viraj A Master, Vsevolod Matveev, Andrea Necchi, Vignesh T Packiam, Sunil H Patel, Taylor Peak, Charles C Peyton, Phillip M Pierorazio, Gagan Prakash, Keyan Salari, Wade J Sexton, Nirmish Singla, Philippe E Spiess, Sarah P Psutka","doi":"10.1016/j.euf.2024.07.017","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>There are limited data on the prevalence and management of testicular germ cell tumor (TGCT) cases presenting with venous tumor thrombus (VTT). Our objectives were to describe the prevalence of TGCT with VTT, to identify a multicenter retrospective cohort, and to ascertain expert opinion regarding optimal management of this entity.</p><p><strong>Methods: </strong>Using the IBM Marketscan database, we identified men with testicular cancer who underwent retroperitoneal lymph node dissection (RPLND) with concurrent VTT or inferior vena cava (IVC) tumor thrombectomy to estimate the prevalence of VTT in TGCT. To identify a multicenter retrospective cohort of patients, we surveyed surgeons and described the presentation, management, and outcomes for the cohort.</p><p><strong>Key findings and limitations: </strong>The prevalence of TGCT with VTT in the IBM Marketscan database was 0.3% (n = 7/2517) when using stringent criteria and 3.1% (n = 79/2517) when using broad criteria. In response to our survey, 16 surgeons from ten centers contributed data for 34 patients. Most patients (n = 29, 85%) presented with nonseminomatous germ cell tumor. Surgical management was used for 93.9% (n = 31), including postchemotherapy tumor thrombectomy with primary cavorrhaphy in 63%. The Marketscan analysis was limited to insured individuals and did not include clinicopathological details, and use of billing codes may have included patients with stromal tumors. In addition, lack of responses to the anonymous survey limited data capture, and the RedCap survey did not address symptoms specific to IVC obstruction or allow central review of the imaging leading to VTT diagnosis.</p><p><strong>Conclusions and clinical implications: </strong>VTT among males with TGCT is rare and requires complex multidisciplinary management, including venous tumor thrombectomy at the time of postchemotherapy RPLND.</p><p><strong>Patient summary: </strong>Using a medical database, we estimated that the frequency of testicular cancer cases in which the tumor extends into a blood vessel (called venous tumor thrombus, VTT) is just 0.3-3.1%. We carried out a survey of surgeons with experience of this condition. Our results indicate that although testicular cancers respond well to chemotherapy, VTT is less responsive and complex surgery is necessary for this rare condition.</p>","PeriodicalId":4,"journal":{"name":"ACS Applied Energy Materials","volume":null,"pages":null},"PeriodicalIF":5.4000,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Testicular Germ Cell Tumors with Venous Tumor Thrombus: Prevalence, Presentation, and Management.\",\"authors\":\"Sophia Y Chahine, Khalid Y Alkhatib, Gevorg Arakelyan, Claire Buxton, Gianluca Giannarini, Robert J Hamilton, Sarah K Holt, Jean-Christophe Bernhard, Di Maria Jiang, Daniel Lin, Jen-Jane Liu, Brandon Manley, Viraj A Master, Vsevolod Matveev, Andrea Necchi, Vignesh T Packiam, Sunil H Patel, Taylor Peak, Charles C Peyton, Phillip M Pierorazio, Gagan Prakash, Keyan Salari, Wade J Sexton, Nirmish Singla, Philippe E Spiess, Sarah P Psutka\",\"doi\":\"10.1016/j.euf.2024.07.017\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objective: </strong>There are limited data on the prevalence and management of testicular germ cell tumor (TGCT) cases presenting with venous tumor thrombus (VTT). Our objectives were to describe the prevalence of TGCT with VTT, to identify a multicenter retrospective cohort, and to ascertain expert opinion regarding optimal management of this entity.</p><p><strong>Methods: </strong>Using the IBM Marketscan database, we identified men with testicular cancer who underwent retroperitoneal lymph node dissection (RPLND) with concurrent VTT or inferior vena cava (IVC) tumor thrombectomy to estimate the prevalence of VTT in TGCT. To identify a multicenter retrospective cohort of patients, we surveyed surgeons and described the presentation, management, and outcomes for the cohort.</p><p><strong>Key findings and limitations: </strong>The prevalence of TGCT with VTT in the IBM Marketscan database was 0.3% (n = 7/2517) when using stringent criteria and 3.1% (n = 79/2517) when using broad criteria. In response to our survey, 16 surgeons from ten centers contributed data for 34 patients. Most patients (n = 29, 85%) presented with nonseminomatous germ cell tumor. Surgical management was used for 93.9% (n = 31), including postchemotherapy tumor thrombectomy with primary cavorrhaphy in 63%. The Marketscan analysis was limited to insured individuals and did not include clinicopathological details, and use of billing codes may have included patients with stromal tumors. In addition, lack of responses to the anonymous survey limited data capture, and the RedCap survey did not address symptoms specific to IVC obstruction or allow central review of the imaging leading to VTT diagnosis.</p><p><strong>Conclusions and clinical implications: </strong>VTT among males with TGCT is rare and requires complex multidisciplinary management, including venous tumor thrombectomy at the time of postchemotherapy RPLND.</p><p><strong>Patient summary: </strong>Using a medical database, we estimated that the frequency of testicular cancer cases in which the tumor extends into a blood vessel (called venous tumor thrombus, VTT) is just 0.3-3.1%. We carried out a survey of surgeons with experience of this condition. Our results indicate that although testicular cancers respond well to chemotherapy, VTT is less responsive and complex surgery is necessary for this rare condition.</p>\",\"PeriodicalId\":4,\"journal\":{\"name\":\"ACS Applied Energy Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.4000,\"publicationDate\":\"2024-08-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Energy Materials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.euf.2024.07.017\",\"RegionNum\":3,\"RegionCategory\":\"材料科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, PHYSICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Energy Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.euf.2024.07.017","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, PHYSICAL","Score":null,"Total":0}
引用次数: 0

摘要

背景和目的:关于伴有静脉瘤栓(VTT)的睾丸生殖细胞瘤(TGCT)病例的发病率和治疗方法的数据十分有限。我们的目的是描述伴有 VTT 的睾丸生殖细胞瘤的发病率,确定一个多中心回顾性队列,并就这一实体的最佳治疗方法确定专家意见:利用 IBM Marketscan 数据库,我们确定了接受腹膜后淋巴结清扫术 (RPLND) 并同时进行 VTT 或下腔静脉 (IVC) 肿瘤血栓切除术的男性睾丸癌患者,以估算 VTT 在 TGCT 中的发病率。为了确定一个多中心回顾性患者队列,我们对外科医生进行了调查,并描述了该队列的表现、管理和结果:在 IBM Marketscan 数据库中,如果采用严格标准,TGCT 伴有 VTT 的患病率为 0.3%(n = 7/2517),如果采用宽泛标准,患病率为 3.1%(n = 79/2517)。针对我们的调查,来自 10 个中心的 16 位外科医生提供了 34 位患者的数据。大多数患者(n = 29,85%)患有非肉芽肿性生殖细胞瘤。93.9%的患者(31人)接受了手术治疗,其中63%的患者接受了化疗后肿瘤血栓切除术和原发性瓣膜成形术。Marketscan 分析仅限于投保人,不包括临床病理学细节,使用的账单代码可能包含了间质瘤患者。此外,匿名调查缺乏回应也限制了数据采集,RedCap调查没有涉及IVC阻塞的特殊症状,也不允许对导致VTT诊断的影像学进行集中审查:在患有 TGCT 的男性中,VTT 比较罕见,需要进行复杂的多学科治疗,包括在化疗后 RPLND 时进行静脉肿瘤血栓切除术。患者摘要:我们利用医疗数据库估计,肿瘤延伸至血管(称为静脉肿瘤血栓,VTT)的睾丸癌病例发生率仅为 0.3-3.1%。我们对对此有经验的外科医生进行了调查。我们的调查结果表明,虽然睾丸癌对化疗反应良好,但 VTT 的反应较差,这种罕见情况需要进行复杂的手术。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Testicular Germ Cell Tumors with Venous Tumor Thrombus: Prevalence, Presentation, and Management.

Background and objective: There are limited data on the prevalence and management of testicular germ cell tumor (TGCT) cases presenting with venous tumor thrombus (VTT). Our objectives were to describe the prevalence of TGCT with VTT, to identify a multicenter retrospective cohort, and to ascertain expert opinion regarding optimal management of this entity.

Methods: Using the IBM Marketscan database, we identified men with testicular cancer who underwent retroperitoneal lymph node dissection (RPLND) with concurrent VTT or inferior vena cava (IVC) tumor thrombectomy to estimate the prevalence of VTT in TGCT. To identify a multicenter retrospective cohort of patients, we surveyed surgeons and described the presentation, management, and outcomes for the cohort.

Key findings and limitations: The prevalence of TGCT with VTT in the IBM Marketscan database was 0.3% (n = 7/2517) when using stringent criteria and 3.1% (n = 79/2517) when using broad criteria. In response to our survey, 16 surgeons from ten centers contributed data for 34 patients. Most patients (n = 29, 85%) presented with nonseminomatous germ cell tumor. Surgical management was used for 93.9% (n = 31), including postchemotherapy tumor thrombectomy with primary cavorrhaphy in 63%. The Marketscan analysis was limited to insured individuals and did not include clinicopathological details, and use of billing codes may have included patients with stromal tumors. In addition, lack of responses to the anonymous survey limited data capture, and the RedCap survey did not address symptoms specific to IVC obstruction or allow central review of the imaging leading to VTT diagnosis.

Conclusions and clinical implications: VTT among males with TGCT is rare and requires complex multidisciplinary management, including venous tumor thrombectomy at the time of postchemotherapy RPLND.

Patient summary: Using a medical database, we estimated that the frequency of testicular cancer cases in which the tumor extends into a blood vessel (called venous tumor thrombus, VTT) is just 0.3-3.1%. We carried out a survey of surgeons with experience of this condition. Our results indicate that although testicular cancers respond well to chemotherapy, VTT is less responsive and complex surgery is necessary for this rare condition.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
ACS Applied Energy Materials
ACS Applied Energy Materials Materials Science-Materials Chemistry
CiteScore
10.30
自引率
6.20%
发文量
1368
期刊介绍: ACS Applied Energy Materials is an interdisciplinary journal publishing original research covering all aspects of materials, engineering, chemistry, physics and biology relevant to energy conversion and storage. The journal is devoted to reports of new and original experimental and theoretical research of an applied nature that integrate knowledge in the areas of materials, engineering, physics, bioscience, and chemistry into important energy applications.
期刊最新文献
Red ginseng polysaccharide promotes ferroptosis in gastric cancer cells by inhibiting PI3K/Akt pathway through down-regulation of AQP3. Diagnostic value of 18F-PSMA-1007 PET/CT for predicting the pathological grade of prostate cancer. Correction. Wilms' tumor 1 -targeting cancer vaccine: Recent advancements and future perspectives. Toll-like receptor agonists as cancer vaccine adjuvants.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1